Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells.
暂无分享,去创建一个
M. Peschanski | L. Jones | N. Déglon | N. Allen | A. Perrier | M. Feyeux | A. Bugi | Sophie Aubert | N. Lefort | P. Giles | C. Bonnefond | Marta Ruíz | A. Redfern | Fany Bourgois-Rocha
[1] S. Dunnett,et al. Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease , 2012, Brain Research Bulletin.
[2] Lin Du,et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets , 2011, Nature Medicine.
[3] John R. Yates,et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of TORC1 and CREB transcriptional pathway , 2011, Nature Medicine.
[4] M. Peschanski,et al. Human pluripotent stem cells for disease modelling and drug screening. , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.
[5] R. Faull,et al. Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain , 2011, Nature Methods.
[6] M. MacDonald,et al. HD CAG-correlated gene expression changes support a simple dominant gain of function. , 2011, Human molecular genetics.
[7] D. Kiel,et al. Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms , 2011, PLoS genetics.
[8] Martin Posch,et al. Cross-platform comparison of microarray data using order restricted inference , 2011, Bioinform..
[9] U. Schmidt,et al. Derivation of Huntington's disease-affected human embryonic stem cell lines. , 2011, Stem cells and development.
[10] C. Ross,et al. Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.
[11] Jinqiu Zhang,et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. , 2011, Cell stem cell.
[12] M. Beal,et al. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. , 2010, Human molecular genetics.
[13] Yohanns Bellaiche,et al. Huntingtin Is Required for Mitotic Spindle Orientation and Mammalian Neurogenesis , 2010, Neuron.
[14] Elena Cattaneo,et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.
[15] M. Hayden,et al. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. , 2010, Human molecular genetics.
[16] Lei Yang,et al. Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.
[17] M. Peschanski,et al. High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis , 2010, In Vitro Cellular & Developmental Biology - Animal.
[18] K. Suk,et al. Identification of novel cell migration‐promoting genes by a functional genetic screen , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] N. Déglon,et al. Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.
[20] M. Beal,et al. Impaired PGC-1alpha function in muscle in Huntington's disease. , 2009, Human molecular genetics.
[21] A. Viale,et al. Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs , 2009, Nature.
[22] T. Gu,et al. Phosphorylation of the SSBP2 and ABL proteins by the ZNF198‐FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide‐specific MS , 2009, Proteomics.
[23] Roland Nilsson,et al. A Computational Screen for Regulators of Oxidative Phosphorylation Implicates SLIRP in Mitochondrial RNA Homeostasis , 2009, PLoS genetics.
[24] Ling Liu,et al. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti‐aging and metabolic effects of sirtuins , 2009, Proteomics.
[25] M. Tomishima,et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.
[26] James A. Thomson,et al. Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.
[27] Beate Sick,et al. Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry , 2008, The Journal of Neuroscience.
[28] Hyman M. Schipper,et al. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray , 2007, Neurobiology of Aging.
[29] J. Cha,et al. Transcriptional signatures in Huntington's disease , 2007, Progress in Neurobiology.
[30] Mauro Delorenzi,et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood , 2007, Proceedings of the National Academy of Sciences.
[31] Mauro Delorenzi,et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.
[32] N. Déglon,et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] J. Olson,et al. Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.
[34] J. Growdon,et al. Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.
[35] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[36] Dimitri Krainc,et al. Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.
[37] J. Olson,et al. Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.
[38] P. Devroey,et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. , 2006, Human reproduction.
[39] Katalin Illes,et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. , 2006, Human molecular genetics.
[40] S. Rechitsky,et al. Preimplantation genetic diagnosis as a source of human embryonic stem cell lines with genetic disorders , 2008 .
[41] R V Jensen,et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] A. Dürr,et al. Akt is altered in an animal model of Huntington's disease and in patients , 2005, The European journal of neuroscience.
[43] Fabrice P Cordelières,et al. Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.
[44] Karen Marder,et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[45] D. Rubinsztein,et al. Decreased cAMP Response Element-mediated Transcription , 2004, Journal of Biological Chemistry.
[46] D. Rubinsztein,et al. Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.
[47] P. Puigserver,et al. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.
[48] D. Rubinsztein,et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. , 2002, Human molecular genetics.
[49] Christopher A. Ross,et al. Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.
[50] Long Yu,et al. Protein inhibitor of neuronal nitric oxide synthase interacts with protein kinase A inhibitors. , 2002, Brain research. Molecular brain research.
[51] D. Rubinsztein,et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.
[52] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[53] R. Carraway,et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.